These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 21119545

  • 1. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP.
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [Abstract] [Full Text] [Related]

  • 2. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
    Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA.
    Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
    [Abstract] [Full Text] [Related]

  • 3. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV.
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M.
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [Abstract] [Full Text] [Related]

  • 5. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
    Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N.
    Respirology; 2011 Nov; 16(8):1210-20. PubMed ID: 21801275
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M.
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M.
    Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
    [Abstract] [Full Text] [Related]

  • 8. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M.
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [Abstract] [Full Text] [Related]

  • 9. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
    Novello S, Pimentel FL, Douillard JY, O'Brien M, von Pawel J, Eckardt J, Liepa AM, Simms L, Visseren-Grul C, Paz-Ares L.
    J Thorac Oncol; 2010 Oct; 5(10):1602-8. PubMed ID: 20808252
    [Abstract] [Full Text] [Related]

  • 10. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C.
    BMC Cancer; 2010 Mar 08; 10():85. PubMed ID: 20211022
    [Abstract] [Full Text] [Related]

  • 11. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M.
    J Thorac Oncol; 2009 Dec 08; 4(12):1530-6. PubMed ID: 19755925
    [Abstract] [Full Text] [Related]

  • 12. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
    Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA, Alliance for Clinical Trials in Oncology.
    J Thorac Oncol; 2014 Feb 08; 9(2):214-21. PubMed ID: 24419419
    [Abstract] [Full Text] [Related]

  • 13. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar 08; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 14. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, Scagliotti G.
    Clin Lung Cancer; 2012 Jan 08; 13(1):24-30. PubMed ID: 21831719
    [Abstract] [Full Text] [Related]

  • 15. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.
    J Clin Oncol; 2008 Jul 20; 26(21):3543-51. PubMed ID: 18506025
    [Abstract] [Full Text] [Related]

  • 16. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A.
    Clin Lung Cancer; 2014 Mar 20; 15(2):166-70. PubMed ID: 24418693
    [Abstract] [Full Text] [Related]

  • 17. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
    Cohen MH, Justice R, Pazdur R.
    Oncologist; 2009 Sep 20; 14(9):930-5. PubMed ID: 19737998
    [Abstract] [Full Text] [Related]

  • 18. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.
    Clin Lung Cancer; 2010 Mar 01; 11(2):126-31. PubMed ID: 20199979
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG.
    Lung Cancer; 2014 Sep 01; 85(3):408-14. PubMed ID: 25088661
    [Abstract] [Full Text] [Related]

  • 20. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
    Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A, Dalphin JC, Westeel V.
    J Thorac Oncol; 2009 Dec 01; 4(12):1544-9. PubMed ID: 19884862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.